ABM Industries, Inc. (ABM) Reaches $39.07 Yearly Low; Karyopharm Therapeutics (KPTI) Covered By 11 Bullish Analysts Last Week

September 7, 2017 - By wolcottdaily

Among 12 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 11 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 20 analyst reports since August 11, 2015 according to SRatingsIntel. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The rating was initiated by Jefferies on Wednesday, September 9 with “Buy”. The firm has “Buy” rating given on Friday, June 23 by Cantor Fitzgerald. The firm earned “Overweight” rating on Wednesday, September 2 by JP Morgan. H.C. Wainwright maintained it with “Buy” rating and $16 target in Thursday, September 8 report. As per Tuesday, August 30, the company rating was upgraded by Jefferies. Bank of America downgraded the shares of KPTI in report on Tuesday, March 15 to “Underperform” rating. Leerink Swann maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) rating on Tuesday, August 11. Leerink Swann has “Outperform” rating and $41 target. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) has “Buy” rating given on Wednesday, August 12 by MLV. The rating was initiated by Robert W. Baird with “Outperform” on Tuesday, June 28. See Karyopharm Therapeutics Inc (NASDAQ:KPTI) latest ratings:

08/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $18.0000 Maintain
23/06/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $18.0000 Maintain

The stock of ABM Industries, Inc. (NYSE:ABM) hit a new 52-week low and has $36.34 target or 7.00% below today’s $39.07 share price. The 7 months bearish chart indicates high risk for the $2.18 billion company. The 1-year low was reported on Sep, 7 by Barchart.com. If the $36.34 price target is reached, the company will be worth $152.60 million less. About 132,061 shares traded. ABM Industries, Inc. (NYSE:ABM) has risen 26.04% since September 7, 2016 and is uptrending. It has outperformed by 9.34% the S&P500.

Investors sentiment increased to 1.11 in 2016 Q4. Its up 0.22, from 0.89 in 2016Q3. It is positive, as 21 investors sold ABM Industries, Inc. shares while 68 reduced holdings. 32 funds opened positions while 63 raised stakes. 50.25 million shares or 0.13% more from 50.18 million shares in 2016Q3 were reported. Credit Suisse Ag holds 0% or 99,795 shares in its portfolio. Blackrock Inv Mngmt Ltd Com has invested 0.01% in ABM Industries, Inc. (NYSE:ABM). Third Avenue Mngmt Limited Liability holds 0.17% or 89,857 shares. Boston Ptnrs accumulated 800,477 shares or 0.04% of the stock. Aperio Group Inc Limited Liability Company holds 0.01% of its portfolio in ABM Industries, Inc. (NYSE:ABM) for 31,477 shares. Principal Gp Inc reported 0.05% of its portfolio in ABM Industries, Inc. (NYSE:ABM). Rhumbline Advisers accumulated 0.01% or 104,861 shares. Grp Inc holds 0.01% or 40,870 shares. Blackrock Institutional Trust Company Na, California-based fund reported 1.75 million shares. Credit Agricole S A holds 38,713 shares. Robeco Institutional Asset Management Bv, a Netherlands-based fund reported 232,893 shares. 154 were accumulated by Northwestern Mutual Wealth Com. Peak6 Investments L P holds 0% or 5,355 shares in its portfolio. Atlantic Group Llc invested in 0% or 18,162 shares. Paloma Partners Management Co invested 0.09% in ABM Industries, Inc. (NYSE:ABM).

ABM Industries Incorporated is a provider of integrated facility solutions. The company has market cap of $2.18 billion. The Firm operates through five divisions: Janitorial, Facility Services, Parking, Building & Energy Solutions, and other. It has a 24.63 P/E ratio. The Company’s Janitorial segment provides a range of cleaning services for commercial office buildings, data centers, educational institutions, government buildings, health facilities, industrial buildings, retail stores, sport event facilities and transportation hubs.

Among 4 analysts covering ABM Industries (NYSE:ABM), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. ABM Industries had 11 analyst reports since August 31, 2015 according to SRatingsIntel. The stock has “In-Line” rating by Imperial Capital on Thursday, June 23. On Monday, August 31 the stock rating was downgraded by Zacks to “Buy”. Imperial Capital maintained the shares of ABM in report on Wednesday, January 4 with “In-Line” rating. The firm has “Outperform” rating by Robert W. Baird given on Thursday, March 9. The stock has “Sector Weight” rating by KeyBanc Capital Markets on Thursday, October 29. The firm has “Buy” rating by Robert W. Baird given on Thursday, August 24. The firm has “Neutral” rating by Sidoti given on Wednesday, November 16. Robert W. Baird downgraded it to “Neutral” rating and $46 target in Tuesday, December 6 report. The firm earned “Buy” rating on Wednesday, May 31 by Robert W. Baird. The stock has “Buy” rating by Sidoti on Thursday, July 13.

Since March 10, 2017, it had 0 buys, and 6 selling transactions for $380,850 activity. Another trade for 950 shares valued at $39,786 was made by JACOBSEN RENE on Monday, April 10. CHIN DEAN A also sold $42,720 worth of ABM Industries, Inc. (NYSE:ABM) shares. 1,970 shares were sold by MCCLURE JAMES P, worth $87,468. CHAVEZ LINDA also sold $216,059 worth of ABM Industries, Inc. (NYSE:ABM) on Friday, March 10.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The company has market cap of $487.89 million. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It currently has negative earnings. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export compounds that inhibit the nuclear export protein, XPO1.

Investors sentiment increased to 1.56 in 2016 Q4. Its up 0.40, from 1.16 in 2016Q3. It improved, as 5 investors sold Karyopharm Therapeutics Inc shares while 15 reduced holdings. 14 funds opened positions while 34 raised stakes. 24.99 million shares or 9.31% more from 22.86 million shares in 2016Q3 were reported. Jpmorgan Chase And reported 412,376 shares. First Personal Svcs reported 1,187 shares. Vanguard Group Incorporated stated it has 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Utd Automobile Association reported 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Commercial Bank Of Montreal Can owns 16,318 shares. Highbridge Capital Mgmt Lc accumulated 39,965 shares. Ny State Common Retirement Fund reported 29,430 shares. Blackrock Investment Limited holds 103,508 shares or 0% of its portfolio. Bancshares Of America De owns 45,819 shares. Mutual Of America Cap Management Limited Liability has 0.02% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Citigroup reported 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Credit Suisse Ag stated it has 17,859 shares or 0% of all its holdings. Great West Life Assurance Can invested in 0% or 1,658 shares. Jacobs Levy Equity Inc holds 0.01% in Karyopharm Therapeutics Inc (NASDAQ:KPTI) or 43,600 shares. California State Teachers Retirement System holds 0% or 55,844 shares in its portfolio.

About 1,200 shares traded. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 21.19% since September 7, 2016 and is uptrending. It has outperformed by 4.49% the S&P500.